CTOs on the Move

Althea Technologies

www.altheatech.com

 
Althea Technologies, Inc., based in San Diego, CA, is focused on reducing the time, risk, and overall cost of our partner's drug development efforts. We apply immediate resources, unsurpassed scientific expertise, and a vast knowledge of regulatory
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Gulf Coast Center

Gulf Coast Center is a Galveston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

All Stat Home Healthcare

All Stat Home Health provides a full range of In-Home and Private Duty Home Health Care, catering specifically to the needs of the patient and family. We supply nursing personnel to Hospitals, Nursing Centers, Doctor's Offices and for private duty

Histogen

A regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. Two product families - a proprietary liquid complex of embryonic-like proteins and growth factors` and a human Extracellular Matrix (ECM) material` ExCeltrix..

Bioscan, Inc.

Bioscan, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Washington, DC. To find more information about Bioscan, Inc., please visit www.bioscan.com

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.